Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
haNK for Infusion in Advanced Solid Tumors
NCT03027128Phase 1Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2017
- Primary completion
- May 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of haNK in solid tumor (3 cohorts), sponsored by ImmunityBio, Inc. Primary endpoints: Maximum Tolerated Dose or Highest Tested Dose at 28 days, Dose-limiting Toxicities at 28 days and 1 more. Started Aug 2017; status: completed.
02
Drugs
haNK
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03027128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027128.